QurAlis NEWS

QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)

May 13, 2020

CAMBRIDGE, Mass., May 13, 2020— QurAlis Corporation, a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the raise of a…

QurAlis wins the Pfizer Golden Ticket!

November 9, 2018

QurAlis has won the Pfizer Golden Ticket! to read more click here.

An Appalachian odyssey: Hunting for ALS genes along a sprawling family tree

August 7, 2018

The man had come for a third opinion. Other doctors had told him he had amyotrophic lateral sclerosis, or ALS, a neuromuscular disease that causes progressive paralysis, but he didn’t…

Discovery Advances

May 22, 2018

We successfully generated a crystal structure of one of our early lead molecules in complex with our molecular target. This structure is currently being used to design new compounds.

QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS

April 5, 2018

CAMBRIDGE, Mass., April 5, 2018. QurAlis Corporation, a new private biotech company focused on developing precision solutions to cure ALS, today announced the addition of biotech investors MP Healthcare Venture…

QurAlis has won the Amgen Golden Ticket at LabCentral

December 15, 2017

CAMBRIDGE, Mass., Dec. 15, 2017 QurAlis was chosen by an Amgen internal committee and live audience members at a “Quick Pitch” event hosted by Amgen at its Cambridge R&D and Operations…